Open AccessPHARMACOECONOMIC EVALUATION FOR DENGUE VACCINE PRICING FOR MALAYSIA: TOWARDS AFFORDABILITY, COST EFFECTIVENESS AND SUSTAINABILITY
Author(s) -
Hock Lye Koh,
Su Yean Teh,
Noorliza M. Noordin,
Lokman Hakim Sulaiman
Publication year - 2017
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2017v10s3.21352
Subject(s) - dengue vaccine , dengue fever , christian ministry , sustainability , cost effectiveness , medicine , dengue virus , environmental economics , economics , risk analysis (engineering) , virology , ecology , philosophy , theology , biology
Objective: Malaysian health ministry is currently evaluating the licensing of dengue vaccine Dengvaxia using a set of criteria including safety, efficacy and cost-effectiveness. The purpose of this research is to formulate a model framework to assist transparent decision-making.Methods: To quantify the cost-effective price of vaccine, pharmacoeconomic evaluation models are commonly used. We review in this paper dengue economic burdens and pharmacoeconomic models, with particular reference to cost-effectiveness.Results: A major weakness in current pharmacoeconomic models is the omission of cost of vaccine production, which is two orders of magnitude lower than the market price. This paper proposes an inclusive model that yields a highly cost-effective threshold price of dengue vaccine at USD 5 per dose for Malaysia.Conclusion: At USD 5 per dose, Dengue vaccine will be fair, Affordable and sustainable.